Countervail competes and is selected for participation in the SBIR sponsored Commercialization Acceleration Program (CAP). October 14, 2015 • admin • Funding, General News Read More »
Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. August 3, 2015 • admin • Funding, General News Read More »
US Patent application submitted for novel OP Exposure Diagnostic Test. June 23, 2015 • admin • General News, Pharmaceuticals Read More »
Countervail Corporation presents significant results of orally dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held at the New York Academy of Sciences. June 17, 2015 • admin • Funding, Grants Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
Countervail holds second pre-IND meeting with Neurology Division of the FDA for guidance on development of a neuroprotectant against nerve agent exposure. February 20, 2015 • admin • General News, Pharmaceuticals Read More »
European patent for the use of galantamine as Method of Treating Organophosphorus Poisoning was granted and registered in Germany, Italy, France, UK, Spain, Turkey, Austria, Poland and Sweden. August 13, 2014 • admin • Agriculture, Military, Pharmaceuticals Read More »
Exclusive worldwide license agreement signed with the University of California at San Diego for two new, novel oxime drug technologies. June 18, 2014 • admin • General News, Pharmaceuticals Read More »
Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado. June 7, 2014 • admin • Funding, General News Read More »
US CIP Patent awarded for use of galantamine as Method of Treating Organophosphorus Poisoning. April 3, 2014 • admin • General News Read More »